Schwarz Shops Fesoterodine to Pfizer

Pfizer Inc.'s acquisition of worldwide rights to Schwarz's registration-stage incontinence product fesoterodine for $210 million plus royalties is the most recent milestone in the German company's successful integration of drug development to its legacy marketing organization-and one that nearly guarantees it a substantial revenue stream regardless of how fesoterodine fares in the marketplace.

Schwarz Pharma AG is on a roll. Pfizer Inc. 's acquisition of worldwide rights to Schwarz's registration-stage incontinence product fesoterodine for $210 million plus royalties is the most recent milestone in the German company's successful integration of drug development to its legacy marketing organization—and one that nearly guarantees it a substantial revenue stream regardless of how fesoterodine fares in the marketplace. [See Deal]

The deal gives Pfizer a good shot at prolonging its dominance of the incontinence market, where tolterodine (Detrol) sold almost...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo